Alhomidi Almotiri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alhomidi Almotiri has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Neil P. Rodrigues
European Cancer Stem Cell Research Institute, Cardiff University, School of Biosciences, Cardiff, UK
8 shared publications - Ali Abdelfattah
Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences The Hashemite University Zarqa Jordan
7 shared publications Ali Abdelfattah
3 shared publicationsJuan Bautista Menendez-Gonzalez
European Cancer Stem Cell Research Institute, Cardiff University, School of Biosciences, Cardiff, UK
3 shared publications- Mohammad Irfan
Department of Clinical Laboratory Science College of Applied Medical Sciences Shaqra University 17464 Dawadmi SA
3 shared publications Peter Giles
Wales Gene Park and Wales Cancer Research Centre, Division of Cancer and Genetics, Cardiff University, School of Medicine, Cardiff, UK
3 shared publications
Latest Publications
- Open Access
- 10 March 2026
- Published by Armed Forces Medical Services in Saudi Medical Journal
- Vol. 47 (3) , 418-428
Clinical Significance of IKBKB Mutations: A Focus on IKBKB-Related Immunodeficiency
Inhibitory kappa B kinase beta (IKBKB, IKK2, or IKKβ ) acts as an activator of the nuclear factor (NF)-κ B signaling cascade that is involved in regulating normal physiological processes and is dysregulated in several pathological processes including immunological disorders. Mutations in IKBKB have been found to cause immune deficiency syndromes. Inherited loss-of-function mutations in IKBKB lead to severe or lethal immune deficiency. In this review, the clinical significance of IKBKB mutations will be reviewed in the context of immune deficiency syndromes. All published clinical cases of IKBKB mutations relevant to immune deficiency, either caused by loss- or gain-of-function mutations will be presented to provide a comprehensive overview of the genetic, clinical, and immunological patterns of these mutations. Finally, the challenges and future perspectives in the diagnosis and management of affected patients with this rare condition will be discussed.
- 10 March 2026
- Published by Armed Forces Medical Services in Saudi Medical Journal
- Vol. 47 (3) , 418-428
Open AccessClinical Significance of IKBKB Mutations: A Focus on IKBKB-Related Immunodeficiency
Inhibitory kappa B kinase beta (IKBKB, IKK2, or IKKβ ) acts as an activator of the nuclear factor (NF)-κ B signaling cascade that is involved in regulating normal physiological processes and is dysregulated in several pathological processes including immunological disorders. Mutations in IKBKB have been found to cause immune deficiency syndromes. Inherited loss-of-function mutations in IKBKB lead to severe or lethal immune deficiency. In this review, the clinical significance of IKBKB mutations will be reviewed in the context of immune deficiency syndromes. All published clinical cases of IKBKB mutations relevant to immune deficiency, either caused by loss- or gain-of-function mutations will be presented to provide a comprehensive overview of the genetic, clinical, and immunological patterns of these mutations. Finally, the challenges and future perspectives in the diagnosis and management of affected patients with this rare condition will be discussed.
- Open Access
- 1 January 2026
- Published by Aging and Disease in Aging and disease
Metabolism of Young and Aged Hematopoietic and Acute Myeloid Leukemia Stem Cells: Insights for Rejuvenation and Therapy
Hematopoietic stem cells (HSCs) reside in the adult bone marrow and sustain the lifelong production of blood and immune cells. The processes of HSC quiescence, activation, and aging are complex and are orchestrated by a combination of intrinsic and extrinsic stimuli. Similarly, leukemic stem cells (LSCs) are responsible for the initiation of leukemia and drug resistance. Metabolic adaptations are critical for these processes, and research in this area is rapidly evolving. In this review, the metabolic programs, including glycolysis, mitochondrial metabolism, and amino acid and lipid metabolism, of young HSCs, aged HSCs, leukemia blasts, and LSCs are comparatively presented, with a greater focus on aged HSCs and LSCs, as aging and leukemia represent substantial health challenges. The clinical implications of metabolic vulnerabilities, either for rejuvenating aged HSCs or selectively killing LSCs, are also discussed.
- 1 January 2026
- Published by Aging and Disease in Aging and disease
Open AccessMetabolism of Young and Aged Hematopoietic and Acute Myeloid Leukemia Stem Cells: Insights for Rejuvenation and Therapy
Hematopoietic stem cells (HSCs) reside in the adult bone marrow and sustain the lifelong production of blood and immune cells. The processes of HSC quiescence, activation, and aging are complex and are orchestrated by a combination of intrinsic and extrinsic stimuli. Similarly, leukemic stem cells (LSCs) are responsible for the initiation of leukemia and drug resistance. Metabolic adaptations are critical for these processes, and research in this area is rapidly evolving. In this review, the metabolic programs, including glycolysis, mitochondrial metabolism, and amino acid and lipid metabolism, of young HSCs, aged HSCs, leukemia blasts, and LSCs are comparatively presented, with a greater focus on aged HSCs and LSCs, as aging and leukemia represent substantial health challenges. The clinical implications of metabolic vulnerabilities, either for rejuvenating aged HSCs or selectively killing LSCs, are also discussed.
- Open Access
- 31 July 2025
- Published by Elsevier in Stem Cell Reports
- Vol. 20 (8) , 102596
Impaired DNA damage responses and inflammatory signaling underpin hematopoietic stem cell defects in Gata2 haploinsufficiency
- 31 July 2025
- Published by Elsevier in Stem Cell Reports
- Vol. 20 (8) , 102596
Open AccessImpaired DNA damage responses and inflammatory signaling underpin hematopoietic stem cell defects in Gata2 haploinsufficiency
- Open Access
- 29 March 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
Identification of UBA7 expression downregulation in myelodysplastic neoplasm with SF3B1 mutations
SF3B1 gene mutations are prevalent in myelodysplastic syndrome (MDS) and define a distinct disease subtype. These mutations are associated with dysregulated genes and pathways, offering potential for novel therapeutic approaches. However, the aberrant mRNA alternative splicing landscape in SF3B1-deficient MDS cells remains underexplored. In this study, we investigated the influence of SF3B1 gene alterations on the pre-mRNA splicing landscape in MDS cells using transcriptomic data from two independent MDS cohorts. we identified over 5000 significant differential alternative splicing events associated with SF3B1 mutation. This work corroborates previous studies, showing significant enrichment of MYC activity and heme metabolism in SF3B1 mutant cells. A key novel finding of this study is the identification of a gene expression signature driven by SF3B1 mutations, centered on protein post-translational modifications. Notably, we discovered aberrant alternative splicing of the tumor suppressor gene UBA7, leading to significantly reduced gene expression. This dysregulation implicates UBA7 as a critical player in MDS pathogenesis. Importantly, the clinical relevance of this finding is underscored by the observation that low UBA7 gene expression was associated with poor overall survival in chronic lymphocytic leukemia (CLL), another hematological malignancy with frequent SF3B1 mutations. Furthermore, a similar association between low UBA7 gene expression and poor survival outcomes was observed across multiple tumor types in the TCGA database, highlighting the broader implications of UBA7 dysregulation in cancer biology. These findings provide new insights into the mechanisms by which SF3B1 mutations reshape the pre-mRNA splicing landscape and drive disease pathogenesis in MDS. Furthermore, they underscore the potential of UBA7 as a biomarker to stratify SF3B1-mutant MDS and CLL patients, offering a refined approach for risk assessment and highlighting opportunities for targeted therapeutic interventions.
- 29 March 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
Open AccessIdentification of UBA7 expression downregulation in myelodysplastic neoplasm with SF3B1 mutations
SF3B1 gene mutations are prevalent in myelodysplastic syndrome (MDS) and define a distinct disease subtype. These mutations are associated with dysregulated genes and pathways, offering potential for novel therapeutic approaches. However, the aberrant mRNA alternative splicing landscape in SF3B1-deficient MDS cells remains underexplored. In this study, we investigated the influence of SF3B1 gene alterations on the pre-mRNA splicing landscape in MDS cells using transcriptomic data from two independent MDS cohorts. we identified over 5000 significant differential alternative splicing events associated with SF3B1 mutation. This work corroborates previous studies, showing significant enrichment of MYC activity and heme metabolism in SF3B1 mutant cells. A key novel finding of this study is the identification of a gene expression signature driven by SF3B1 mutations, centered on protein post-translational modifications. Notably, we discovered aberrant alternative splicing of the tumor suppressor gene UBA7, leading to significantly reduced gene expression. This dysregulation implicates UBA7 as a critical player in MDS pathogenesis. Importantly, the clinical relevance of this finding is underscored by the observation that low UBA7 gene expression was associated with poor overall survival in chronic lymphocytic leukemia (CLL), another hematological malignancy with frequent SF3B1 mutations. Furthermore, a similar association between low UBA7 gene expression and poor survival outcomes was observed across multiple tumor types in the TCGA database, highlighting the broader implications of UBA7 dysregulation in cancer biology. These findings provide new insights into the mechanisms by which SF3B1 mutations reshape the pre-mRNA splicing landscape and drive disease pathogenesis in MDS. Furthermore, they underscore the potential of UBA7 as a biomarker to stratify SF3B1-mutant MDS and CLL patients, offering a refined approach for risk assessment and highlighting opportunities for targeted therapeutic interventions.
- Open Access
- 28 March 2025
- Published by Journal of Pure and Applied Microbiology in Journal of Pure and Applied Microbiology
- Vol. 19 (2) , 808-817
Systematic Review on Monitoring Antibiotic-resistant Pathogens in Wastewater
The World Health Organization identifies antimicrobial-resistance (AMR) among the top ten global health threats, potentially causing 10 million deaths annually by 2050. New global infections have created the need to track disease outbreaks and antibiotic-resistance to develop effective public health solutions. This systematic review aims to update the knowledge on antibiotic-resistant bacterial pathogens through wastewater surveillance carried out at different levels and geographical locations. The study initially screened 4467 articles based on the search criteria set for the current study after eliminating duplicates, review articles, systematic reviews, and articles published in languages other than English. Finally, we identified 156 articles, of which 53 were relevant articles for the systematic review and contained wastewater surveillance along with a comparison with clinical strains. After a careful review of the articles, we found two levels that were very important for antibiotic-resistance, one being the level of wastewater surveillance and the other being the method of screening for antibiotic- resistance, such as culture-based methods or genomic screening approaches. From these studies, we found that 52% were conducted at the single-sewer level, followed by clinical settings and international studies. Most international studies used the genomic screening approach, while, as regional studies, national-level studies used culture-based approaches. Although advanced genomic approaches, such as next-generation sequencing, offer greater advantages in predicting antibiotic-resistance genes and AMR surveillance, they cannot overcome the limitations associated with AMR monitoring, such as contamination from animal sources. Overall, this study indicates that the Enterobacteriaceae family is a highly evolving antibiotic-resistant pathogen, followed by the Enterococcaceae family. The use of research with clinical comparisons in wastewater surveillance avoids false-positive predictions and simplifies the process and interpretation of data.
- 28 March 2025
- Published by Journal of Pure and Applied Microbiology in Journal of Pure and Applied Microbiology
- Vol. 19 (2) , 808-817
Open AccessSystematic Review on Monitoring Antibiotic-resistant Pathogens in Wastewater
The World Health Organization identifies antimicrobial-resistance (AMR) among the top ten global health threats, potentially causing 10 million deaths annually by 2050. New global infections have created the need to track disease outbreaks and antibiotic-resistance to develop effective public health solutions. This systematic review aims to update the knowledge on antibiotic-resistant bacterial pathogens through wastewater surveillance carried out at different levels and geographical locations. The study initially screened 4467 articles based on the search criteria set for the current study after eliminating duplicates, review articles, systematic reviews, and articles published in languages other than English. Finally, we identified 156 articles, of which 53 were relevant articles for the systematic review and contained wastewater surveillance along with a comparison with clinical strains. After a careful review of the articles, we found two levels that were very important for antibiotic-resistance, one being the level of wastewater surveillance and the other being the method of screening for antibiotic- resistance, such as culture-based methods or genomic screening approaches. From these studies, we found that 52% were conducted at the single-sewer level, followed by clinical settings and international studies. Most international studies used the genomic screening approach, while, as regional studies, national-level studies used culture-based approaches. Although advanced genomic approaches, such as next-generation sequencing, offer greater advantages in predicting antibiotic-resistance genes and AMR surveillance, they cannot overcome the limitations associated with AMR monitoring, such as contamination from animal sources. Overall, this study indicates that the Enterobacteriaceae family is a highly evolving antibiotic-resistant pathogen, followed by the Enterococcaceae family. The use of research with clinical comparisons in wastewater surveillance avoids false-positive predictions and simplifies the process and interpretation of data.
- Open Access
- 18 January 2025
- Published by Elsevier in Molecular Therapy
- Vol. 33 (6) , 2645-2662
Treating genetic blood disorders in the era of CRISPR-mediated genome editing
- 18 January 2025
- Published by Elsevier in Molecular Therapy
- Vol. 33 (6) , 2645-2662
Open AccessTreating genetic blood disorders in the era of CRISPR-mediated genome editing
- Open Access
- 30 December 2024
- Published by Springer Nature in Journal of Umm Al-Qura University for Medical Science
- Vol. 10 (2) , 1-10
Validation of ABO Gene Expression in Normal Tissues and Acute Myeloid Leukaemia Using In-Silico Approaches
Background:-This study investigates the association between the ABO blood group genes and acute myeloid leukaemia (AML), a cancer characterized by rapid growth of abnormal white blood cells. Prior research indicates a potential link between blood group antigens and various cancers, including leukaemia. Our objective is to assess and validate changes in ABO gene expression in AML tissues compared to normal tissues, clarifying the extent of its association with AML pathogenesis and progression. Methods:-In-silico analysis using platforms like GeneCards, HPA, ARChS4, BioGPS, and GEPIA2 was conducted to gather detailed data on ABO gene localization and its expression at RNA, mRNA, and protein levels in normal. And AML patients, aiding in understanding gene functionality. Results:-The ABO gene was expressed in almost all subcellular components and throughout normal body tissues, including the myeloid tissues. A statistically significant association was found between the ABO gene expression and AML conditions in which the expression of the ABO gene is significantly suppressed in AML. There was worse survival for the AML patient with higher ABO expression without significant statistical evidence. Conclusion:-The results reveal a reverse association between ABO gene expression and AML, highlighting the need for further research to elucidate ABO's role in AML progression.
- 30 December 2024
- Published by Springer Nature in Journal of Umm Al-Qura University for Medical Science
- Vol. 10 (2) , 1-10
Open AccessValidation of ABO Gene Expression in Normal Tissues and Acute Myeloid Leukaemia Using In-Silico Approaches
Background:-This study investigates the association between the ABO blood group genes and acute myeloid leukaemia (AML), a cancer characterized by rapid growth of abnormal white blood cells. Prior research indicates a potential link between blood group antigens and various cancers, including leukaemia. Our objective is to assess and validate changes in ABO gene expression in AML tissues compared to normal tissues, clarifying the extent of its association with AML pathogenesis and progression. Methods:-In-silico analysis using platforms like GeneCards, HPA, ARChS4, BioGPS, and GEPIA2 was conducted to gather detailed data on ABO gene localization and its expression at RNA, mRNA, and protein levels in normal. And AML patients, aiding in understanding gene functionality. Results:-The ABO gene was expressed in almost all subcellular components and throughout normal body tissues, including the myeloid tissues. A statistically significant association was found between the ABO gene expression and AML conditions in which the expression of the ABO gene is significantly suppressed in AML. There was worse survival for the AML patient with higher ABO expression without significant statistical evidence. Conclusion:-The results reveal a reverse association between ABO gene expression and AML, highlighting the need for further research to elucidate ABO's role in AML progression.
- Open Access
- 7 October 2024
- Published by Armed Forces Medical Services in Saudi Medical Journal
- Vol. 45 (10) , 1007-1019
CAR T-cell therapy in acute myeloid leukemia
Acute myeloid leukemia (AML) is an aggressive leukemic malignancy that affects myeloid lineage progenitors. Relapsed or refractory AML patients continue to have poor prognoses, necessitating the development of novel therapy alternatives. Adoptive T-cell therapy with chimeric antigen receptors (CARs) is an intriguing possibility in the field of leukemia treatment. Chimeric antigen receptor T-cell therapy is now being tested in clinical trials (mostly in phase I and phase II) using AML targets including CD33, CD123, and CLL-1. Preliminary data showed promising results. However, due to the cellular and molecular heterogeneity of AML and the co-expression of some AML targets on hematopoietic stem cells, these clinical investigations have shown substantial “on-target off-tumor” toxicities, indicating that more research is required. In this review, the latest significant breakthroughs in AML CAR T cell therapy are presented. Furthermore, the limitations of CAR T-cell technology and future directions to overcome these challenges are discussed.
- 7 October 2024
- Published by Armed Forces Medical Services in Saudi Medical Journal
- Vol. 45 (10) , 1007-1019
Open AccessCAR T-cell therapy in acute myeloid leukemia
Acute myeloid leukemia (AML) is an aggressive leukemic malignancy that affects myeloid lineage progenitors. Relapsed or refractory AML patients continue to have poor prognoses, necessitating the development of novel therapy alternatives. Adoptive T-cell therapy with chimeric antigen receptors (CARs) is an intriguing possibility in the field of leukemia treatment. Chimeric antigen receptor T-cell therapy is now being tested in clinical trials (mostly in phase I and phase II) using AML targets including CD33, CD123, and CLL-1. Preliminary data showed promising results. However, due to the cellular and molecular heterogeneity of AML and the co-expression of some AML targets on hematopoietic stem cells, these clinical investigations have shown substantial “on-target off-tumor” toxicities, indicating that more research is required. In this review, the latest significant breakthroughs in AML CAR T cell therapy are presented. Furthermore, the limitations of CAR T-cell technology and future directions to overcome these challenges are discussed.
- Open Access
- 29 August 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (8) , e0307724
Differential expression and regulation of ADAD1, DMRTC2, PRSS54, SYCE1, SYCP1, TEX101, TEX48, and TMPRSS12 gene profiles in colon cancer tissues and their in vitro response to epigenetic drugs
Colon cancer (CC) is a significant cause of death worldwide, particularly in Saudi Arabia. To increase the accuracy of diagnosis and treatment, it is important to discover new specific biomarkers for CC. The main objectives of this research are to identify potential specific biomarkers for the early diagnosis of CC by analyzing the expressions of eight cancer testis (CT) genes, as well as to analyze how epigenetic mechanisms control the expression of these genes in CC cell lines. Tissue samples were collected from 15 male patients with CC tissues and matched NC tissues for gene expression analysis. The expression levels of specific CT genes, including ADAD1, DMRTC2, PRSS54, SYCE1, SYCP1, TEX101, TEX48, and TMPRSS12, were assessed using quantitative techniques. To validate the gene expression patterns, we used publicly available CC statistics. To investigate the effect of inhibition of DNA methylation and histone deacetylation on CT gene expression, in vitro experiments were performed using HCT116 and Caco-2 cell lines. There was no detected expression of the genes neither in the patient samples nor in NC tissues, except for TEX48, which exhibited upregulation in CC samples compared to NC tissues in online datasets. Notably, CT genes showed expression in testis samples. In vitro, experiments demonstrated significant enhancement in mRNA expression levels of ADAD1, DMRTC2, PRSS54, SYCE1, SYCP1, TEX101, TEX48, and TMPRSS12 following treatment with 5-aza-2’-deoxycytidine and trichostatin A in HCT116 and Caco-2 cell lines. Epigenetic treatments modify the expression of CT genes, indicating that these genes can potentially be used as biomarkers for CC. The importance of conducting further research to understand and target epigenetic mechanisms to improve CC treatment cannot be overemphasized.
- 29 August 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (8) , e0307724
Open AccessDifferential expression and regulation of ADAD1, DMRTC2, PRSS54, SYCE1, SYCP1, TEX101, TEX48, and TMPRSS12 gene profiles in colon cancer tissues and their in vitro response to epigenetic drugs
Colon cancer (CC) is a significant cause of death worldwide, particularly in Saudi Arabia. To increase the accuracy of diagnosis and treatment, it is important to discover new specific biomarkers for CC. The main objectives of this research are to identify potential specific biomarkers for the early diagnosis of CC by analyzing the expressions of eight cancer testis (CT) genes, as well as to analyze how epigenetic mechanisms control the expression of these genes in CC cell lines. Tissue samples were collected from 15 male patients with CC tissues and matched NC tissues for gene expression analysis. The expression levels of specific CT genes, including ADAD1, DMRTC2, PRSS54, SYCE1, SYCP1, TEX101, TEX48, and TMPRSS12, were assessed using quantitative techniques. To validate the gene expression patterns, we used publicly available CC statistics. To investigate the effect of inhibition of DNA methylation and histone deacetylation on CT gene expression, in vitro experiments were performed using HCT116 and Caco-2 cell lines. There was no detected expression of the genes neither in the patient samples nor in NC tissues, except for TEX48, which exhibited upregulation in CC samples compared to NC tissues in online datasets. Notably, CT genes showed expression in testis samples. In vitro, experiments demonstrated significant enhancement in mRNA expression levels of ADAD1, DMRTC2, PRSS54, SYCE1, SYCP1, TEX101, TEX48, and TMPRSS12 following treatment with 5-aza-2’-deoxycytidine and trichostatin A in HCT116 and Caco-2 cell lines. Epigenetic treatments modify the expression of CT genes, indicating that these genes can potentially be used as biomarkers for CC. The importance of conducting further research to understand and target epigenetic mechanisms to improve CC treatment cannot be overemphasized.